摘要
目的 :研究XIAP基因在前列腺癌细胞系和前列腺癌组织的表达情况 ,及其与前列腺癌临床病理特征的关系。 方法 :应用RT PCR检测前列腺癌组织、正常前列腺组织和前列腺癌细胞株PC 3,DU 14 5 ,LNCaP细胞XIAP基因的表达 ,并通过免疫组化SP法检测 5 6例前列腺癌组织标本XIAP蛋白的表达情况。 结果 :XIAP基因在前列腺癌组织和前列腺癌细胞株PC 3,DU 14 5 ,LNCaP细胞高表达 ,正常前列腺组织无表达。在前列腺癌组织和癌旁组织中 ,XIAP蛋白阳性检出率分别为 5 3.6 % (30 / 5 6 )和 2 1.5 % (12 / 5 6 ) (P <0 .0 1) ;不同分期、分级组XIAP阳性检出率相比差异无显著性 (P >0 .0 5 )。 结论 :凋亡抑制基因XIAP与前列腺癌相关 ,在前列腺癌发生过程中具有重要的作用 ,有可能成为前列腺癌治疗的靶标。
Objective: To study the expression of the inhibitor of apoptosis (IAP) gene XIAP in prostate cancer and the relationship between its expression and its clinical stage or Gleason grade. Methods: XlAP mRNA expression was detected by RT-PCR in three prostate cancer cell lines(PC-3,DU-145,LNCaP), neoplastic prostate tissues and normal prostate tissues. Immunohistochemical SP method was used to examine the expression of XlAP protein in 56 neoplastic prostate tissue specimens. Results: XlAP gene was not expressed in normal prostate tissues, but highly expressed in prostate cancer cell lines PC-3,DU-145,LNCaP. Thirty of the 56( 53.6%) tumor samples were positive XIAP protein, and only 12( 21.5%) paratumor samples were positive XIAP protein(P< 0.01), XIAP positivity not correlated with tumor stage or Gleason grade (P> 0.05). Conclusion: XlAP may be involved in the development of prostate cancer and play an important role in human prostate carcinogenesis. It is likely to be used as a target of prostate cancer therapy.
出处
《中华男科学杂志》
CAS
CSCD
2004年第11期832-835,共4页
National Journal of Andrology
